MrktViz
    Relative StrengthThemesEarningsNewScreensNewChartsNew
    /
    Sign in

    OMEROS CORPORATION

    OMERPharmaceutical Preparations · Avg daily volume 1.4M · fiscal year ends Dec
    $13.21−0.80−5.71%Volume 2.0M+48% vs avg
    Week
    OMEROMEROS CORPORATION · 1DNov 20, 2026
    O13.78H13.88L13.07C13.21−0.80 (−5.71%)ADR5.9%
    This week, day 5 of 5−24.5%range37.6%closed at11% of rangevol1.9× 10-wk avg
    Vol2.0M1.5× avg
    SMA 10
    SMA 2016.91−21.9%
    SMA 5017.83−25.9%
    SMA 20013.84−4.6%

    Performance

    1W−24.5%
    1M−21.6%
    3M−31.6%
    6M+15.3%
    YTD−23.1%
    1Y+60.7%

    Q4 EPS due in ~130 days

    FY (Dec)EPS $ChgHighLow
    2019-1.71–––
    2020-2.41−41%––
    20213.12+230%––
    20220.76−76%––
    2023-1.88−347%––
    2024-2.70−44%143
    2025-0.05+98%183
    TTM1.40217

    Ratings & facts

    RS Rating68 ▼26
    Days at RS 90+0
    Setup checks0 / 3
    EPS chg, last qtr−68%
    EPS acceleratingno
    Sales chg, last qtr–
    P/E (last 4 qtrs)9.4
    Mkt cap$983.7M
    Off 52-wk high-37.8%
    Close Nov 20, 2026

    Quarterly earnings

    Latest filing: 10-Q, 2026-11-16
    Jun ’24FQ2 ’24
    Sep ’24FQ3 ’24
    Dec ’24Q4FQ4 ’24
    Mar ’25FQ1 ’25
    Jun ’25FQ2 ’25
    Sep ’25FQ3 ’25
    Dec ’25Q4FQ4 ’25
    Mar ’26FQ1 ’26
    Jun ’26FQ2 ’26
    Sep ’26FQ3 ’26
    EPS
    EPS
    −$0.97
    −$0.56
    −$0.55
    −$0.58
    −$0.43
    −$0.47
    $1.42
    $0.62
    $0.15
    −$0.79
    % chg
    −64%
    +7%
    −267%
    +8%
    +56%
    +16%
    +358%
    +207%
    +135%
    −68%
    Sales
    –
    –
    –
    0
    0
    0
    –
    9.9M
    28.5M
    35.9M
    % chg
    –
    –
    –
    –
    –
    –
    –
    –
    –
    –
    Filed
    08/14
    11/13
    03/31
    05/15
    08/14
    11/13
    03/31
    05/13
    08/12
    11/16
    EPS growth ≥ 25%0–25%fallingno comparison

    Source: SEC EDGAR 10-Q and 10-K filings, loaded the first time a stock is opened and refreshed daily. Q4 = full year minus the first three quarters. Growth from a loss is measured against the size of the loss (−$1 → $2 = +300%). Analyst estimates are not in EDGAR.

    Relative Strength detail →TradingView ↗Finviz ↗
    MrktViz

    Professional market visualization and analytics platform for traders, analysts, and financial professionals worldwide.

    Product

    • Live Data
    • Analytics
    • API Access
    • Documentation

    Company

    • About
    • Blog
    • Support
    • Contact

    © 2025 MrktViz. All rights reserved.

    Privacy PolicyTerms of Service